eli lilly and company

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and pricing challenges loom. See more here.

Business Insider · 2d

Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before

AOL · 1d

Eli Lilly reports mixed earnings, increases 2025 guidance

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 billion.

Investopedia on MSN · 3d

What Analysts Think of Eli Lilly Stock Ahead of Earnings

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Business Insider · 1d

Eli Lilly And Co. Q4 Profit Increases, Beats Estimates

Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The

The Motley Fool on MSN · 1d

Eli Lilly (LLY) Q4 2024 Earnings Call Transcript

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar,

1don MSN

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

MM&M2d

Inside Eli Lilly’s bold breast cancer awareness ad debut at the Grammys

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

FiercePharma1d

Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

1don MSN

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Yahoo Finance7d

Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the ...

FierceBiotech1d

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

BioSpace15h

After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics